Pfizer to acquire FoldRx Pharma

Pfizer has announced it is to acquire FoldRx Pharmaceuticals, a privately held drug discovery and clinical development company Pfizer has announced it is to acquire FoldRx Pharmaceuticals, a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics. Financial details of the deal have not been disclosed, however, Pfizer will make an upfront payment for FoldRx, followed by further payments on achievement of milestones. FoldRx's portfolio contains both clinical and pre-clinical programmes for investigational compounds to treat diseases caused by protein misfolding, a recognised underlying cause in many chronic degenerative diseases. The company currently has a product candidate in registration for a progressively fatal genetic neurodegenerative disease known as TTR amyloid polyneuropathy (ATTR-PN), for which liver transplant is the only treatment option that is currently available. FoldRx has also filed a marketing authorisation application with the European Medicines Agency (EMA) for tafamidis, which has orphan drug designation in both the US and European Union and Fast Track designation in the US for the treatment of ATTR-PN. "By combining FoldRx's proprietary expertise in identifying and developing treatments for protein misfolding diseases with Pfizer's commercial, medical and regulatory expertise, and global strengths in patient services and reimbursement, we are taking a significant step toward potentially bringing, for the first time, a non-surgical treatment option for underserved patients affected by the deadly disease ATTR-PN," said Geno Germano, president and general manager, Pfizer Specialty Care Business Unit. FoldRx has built its portfolio of preclinical and clinical candidates by using its proprietary yeast-based drug target discovery platform. The company's screening engine can quickly and effectively evaluate potential treatment candidates in a wide range of diseases caused by misfolded proteins. Using this screening engine, FoldRx is also actively engaged in an innovative early drug discovery programme to identify therapeutic agents for cystic fibrosis, Parkinson's disease and Huntington's disease.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!